poisar

Stocks · News reference

Barclays Maintains Overweight on Braze, Raises Price Target to $38

BenzingaBenzinga Newsdesk

Barclays analyst Raimo Lenschow maintains Braze (NASDAQ:BRZE) with a Overweight and raises the price target from $31 to $38.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    UiPath (PATH) Meets Q2 Earnings Estimates

    UiPath reported Q2 2026 earnings of $0.15 per share, matching consensus estimates, with revenues of $410.26 million exceeding expectations by 3.19%. The stock has underperformed the S&P 500 year-to-date, gaining 9.8% versus the market's 12%. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market. The Internet-Software industry ranks in the top 31% of Zacks industries.